High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
M Palafox, L Monserrat, M Bellet, G Villacampa… - Nature …, 2022 - nature.com
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor
activity than endocrine therapy alone for the treatment of advanced estrogen receptor-
positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and
others develop acquired resistance. Here, we show that p16 overexpression is associated
with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n= 37) and
estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and …
activity than endocrine therapy alone for the treatment of advanced estrogen receptor-
positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and
others develop acquired resistance. Here, we show that p16 overexpression is associated
with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n= 37) and
estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and …
[PDF][PDF] High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
M Palafox Sánchez, L Monserrat Vicente… - 2022 - scientiasalut.gencat.cat
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor
activity than endocrine therapy alone for the treatment of advanced estrogen receptor-
positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and
others develop acquired resistance. Here, we show that p16 overexpression is associated
with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n= 37) and
estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and …
activity than endocrine therapy alone for the treatment of advanced estrogen receptor-
positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and
others develop acquired resistance. Here, we show that p16 overexpression is associated
with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n= 37) and
estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and …
以上显示的是最相近的搜索结果。 查看全部搜索结果